Patents by Inventor Roger Francis Bone

Roger Francis Bone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11369606
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • Publication number: 20220143141
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 12, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Publication number: 20220047593
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 17, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Publication number: 20200138813
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Publication number: 20200138814
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Patent number: 10537573
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • Publication number: 20160367554
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: January 20, 2015
    Publication date: December 22, 2016
    Inventors: Brian D KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Patent number: 7030110
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: April 18, 2006
    Assignee: Ortho-McNeil Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Patent number: 6635637
    Abstract: Cyclic oxyguanidine compounds, including compounds of Formulae I and II: wherein R1, R3-R6, R21-R26, L, Y, Z, and A are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formulae I and II. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: October 21, 2003
    Assignee: Dimensional Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Tianbao Lu, Bruce Edward Tomczuk, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Publication number: 20030073702
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: 1
    Type: Application
    Filed: October 4, 2002
    Publication date: April 17, 2003
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Patent number: 6476016
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: November 5, 2002
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Publication number: 20020052357
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: 1
    Type: Application
    Filed: July 17, 2001
    Publication date: May 2, 2002
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Publication number: 20020022615
    Abstract: Cyclic oxyguanidine compounds, including compounds of Formulae I and II: 1
    Type: Application
    Filed: August 2, 2001
    Publication date: February 21, 2002
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Tianbao Lu, Bruce Edward Tomczuk, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone